Scinai Immunotherapeutics Ltd. (SCNI) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Jerusalem, Israel. The current CEO is Amir Reichman.
SCNI has IPO date of 2015-05-11, 31 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $802.37K.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
